Laparoscopy Combined with Enhanced Recovery Pathway in Ileocecal Resection for Crohn’s Disease: A Randomized Study
Table 2
Baseline characteristics and surgical aspects of the included patients per group.
Laparoscopy and ERAS care ()
Laparoscopy and standard care ()
value
Age, year, median (IQR)
31.5 (29.25, 43.50)
29.5 (26.25, 43.50)
NS
Course of disease, month median (IQR)
32 (12, 81)
42 (10.5, 81)
NS
Male sex, (%)
9 (56.3%)
11 (68.8%)
NS
Body mass index, mean (SD, kg/m2)
18.09 ± 2.35
17.68 ± 1.81
NS
ASA (%), grade I or II
100
100
NS
Smoking history, (%)
2 (12.5)
5 (31.3)
NS
Immunosuppressant therapy within 30 days of surgery, (%)
0 (0)
2 (12.5)
NS
Steroid therapy within 30 days of surgery, (%)
0 (0)
1 (6.3)
NS
Operation history, (%)
7 (43.8)
7 (43.8)
NS
Perianal disease, (%)
2 (12.5)
3 (18.8)
NS
Location, (%)
NS
L1 (ileal)
13 (81.3)
12 (75)
L2 (colonic)
0
0
L3 (ileocolonic)
3 (18.8)
4 (25)
Laboratory indices
White blood cell, mean, (SD, ×109/L)
5.66 ± 1.75
6.21 ± 2.76
NS
Hemoglobin, g/L, median (IQR)
11.4 (10.58, 12.98)
12.1 (11.68, 13.78)
NS
C-reactive protein, mg/L, median (IQR)
2.55 (1.025, 10.45)
3.6 (1.15, 13.325)
NS
ESR, mm/h, median (IQR)
9 (6.25, 16)
9 (6, 14.75)
NS
Albumin, g/L, median (IQR)
36.85 (34.15, 38.225)
33.65 (32.15, 32.375)
NS
Preoperative thirst, (%)
1 (6.3)
14 (87.5)
<0.001
Preoperative hunger, (%)
1 (6.3)
14 (87.5)
<0.001
Conversion to open, (%)
0
0
NS
Duration of surgery, minutes, median (IQR)
162.5 (131.25, 180)
180 (152.5, 240)
NS
Blood loss, mL, median (IQR)
30 (20, 37.5)
30 (22.5, 55.5)
NS
ERAS = enhanced recovery after surgery; IQR = interquartile range; SD = standard deviation; ASA = American Society of Anesthesiologists; ESR = erythrocyte sedimentation rate; NS = not significant.
